Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633352 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4SIGMAR1SLC18A3 | |
| SCHEMBL1721954 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4SIGMAR1SLC18A3 | |
| SCHEMBL25803074 | 0.82 | OPRM1 (0.58) | SLC6A2SLC6A3SLC6A4SIGMAR1SLC18A3 | |
| SCHEMBL8205042 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7458617 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7352894 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10194861 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8812053 | 0.80 | SLC6A4 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7560904 | 0.80 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4CHRM1DRD2 | |
| SCHEMBL7561589 | 0.80 | SLC6A4 (0.47) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114475-A1 | Methods for the treatment of addiction | ADDICTION THERAPIES, INC. | 2003-06-19 | — | — | US | claimed |
| WO-2003037313-A2 | METHODS FOR THE TREATMENT OF ADDICTION | RECOVERY PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| CN-105392500-B | Imaging neurological diseases | 通用电气健康护理有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230089353-A1 | METHOD FOR THE PREPARATION OF N-MONOFLUOROALKYL TROPANES AND THEIR USE | ROTOP RADIOPHARMACY GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| EP-3880674-A1 | METHOD FOR THE PREPARATION OF N-MONOFLUOROALKYL TROPANES AND THEIR USE | ROTOP RADIOPHARMACY GMBH (DE) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021148598-A1 | METHOD FOR THE PREPARATION OF N-MONOFLUOROALKYL TROPANES AND THEIR USE | ROTOP RADIOPHARMACY GMBH (DE) | 2021-07-29 | — | — | WO | disclosed |
| US-11051777-B2 | Imaging neurological disease | GE HEALTHCARE LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2019-07-18 | — | — | US | disclosed |
| EP-3024501-B1 | IMAGING NEUROLOGICAL DISEASE | GE HEALTHCARE LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-20020010207-A1 | Tropane analogs and methods for inhibition of monoamine transport | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2002-01-24 | — | — | US | disclosed |
| WO-2001098266-A2 | N-AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001089524-A1 | METHOD OF PROMOTING SMOKING CESSATION | RESEARCH TRIANGLE INSTITUTE (US) | 2001-11-29 | — | — | WO | disclosed |
| US-20010044543-A1 | Imaging agents for diagnosis of Parkinson's disease | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001062301-A2 | IMAGING AGENTS FOR DIAGNOSIS OF PARKINSON'S DISEASE | BIOSTREAM, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001000082-A1 | IMAGING THE DOPAMINE TRANSPORTER TO DETERMINE AD-HD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0944626-A1 | TROPANE DERIVATIVES AND METHOD FOR THEIR SYNTHESIS | GEORGETOWN UNIVERSITY (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5834484-A | USED TO TREAT HUMAN PATIENT SUFFERING FROM COCAINE ADDICTION OR OVERDOSE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998024788-A1 | TROPANE DERIVATIVES AND METHOD FOR THEIR SYNTHESIS | GEORGETOWN UNIVERSITY (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | SLC6A2 239/4885SLC6A3 382/4885SLC6A4 1533/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885SLC6A4 2/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885SLC6A4 2/4885 |
| US-20010044543-A1 | Imaging agents for diagnosis of Parkinson's disease | SLC6A3, SLC18A2, SLC18A3 | SLC6A2 4/4885SLC6A3 1/4885SLC6A4 15/4885 |
| US-11051777-B2 | Imaging neurological disease | SLC18A2, SLC1A2, CDR2 | SLC6A2 28/4885SLC6A3 8/4885SLC6A4 93/4885 |
| US-20230089353-A1 | METHOD FOR THE PREPARATION OF N-MONOFLUOROALKYL TROPANES AND THEIR USE | TTPA, MTTP, TBXA2R | SLC6A2 1076/4885SLC6A3 1469/4885SLC6A4 1162/4885 |
| US-20020010207-A1 | Tropane analogs and methods for inhibition of monoamine transport | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.